Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from MaxCyte ( (MXCT) ).
MaxCyte, Inc. has announced a change in its major holdings, with BlackRock, Inc. acquiring a 7.57% stake in the company as of January 17, 2025. This acquisition reflects a strategic investment by BlackRock, potentially impacting MaxCyte’s influence in the biotechnology sector and signaling confidence in its market position. The notification of this change was completed and disclosed by BlackRock on January 20, 2025.
More about MaxCyte
MaxCyte, Inc. operates in the biotechnology industry, focusing on providing cell-engineering technology and products. It serves a variety of markets, including drug development and industrial biotechnology, offering solutions that enhance the performance of cell-based therapies.
YTD Price Performance: 21.60%
Average Trading Volume: 60,265
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £424.4M
See more insights into MXCT stock on TipRanks’ Stock Analysis page.
